RxDoctor Payments Data

Alan Polackwich, MD

Urology · Miami Beach, FLNPI 1518128768

Payments from drug & device makers

$4,631in general payments, 2019–2025

Across 135 payments — averaging $34.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Coloplast$820
  • Endo Pharmaceuticals Inc.$541
  • Endo USA, Inc.$371
  • Olympus America Inc.$191
  • Myriad Genetic Laboratories, Inc.$175
  • plus $1K from 26 others

What the payments were for

  • Travel & lodging$45910%
  • Food & beverage$4,17190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,631 in reported general payments places this provider in the 50th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$180,052
Medicare patients
675
Services billed
6,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiaflexCollagenase Clostridium Hist.19$250,145
GemtesaVibegron99$71,930
MyrbetriqMirabegron25$20,281
Dutasteride160$5,908
Tadalafil40$4,362
Testosterone50$4,333
Testosterone Cypionate128$4,310
Silodosin32$3,771
Tamsulosin Hcl302$3,025
Alfuzosin Hcl ErAlfuzosin Hcl74$1,172
Potassium Citrate ErPotassium Citrate15$1,110
Finasteride82$843
Sildenafil Citrate108$818
Cabergoline18$655
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Endo Pharmaceuticals Inc.Xiaflex$541$250,14519 claims
Sumitomo Pharma America, Inc.Gemtesa$98$71,93099 claims
Astellas Pharma US IncMyrbetriq$53$20,28125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 urology providers in Florida.

Other urology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →